Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Sep 5, 2007

Bayer Schering Pharma Contracts Dyax to Discover Therapeutic mAbs

  • Dyax inked an agreement with Bayer Schering Pharma for the discovery of therapeutic antibodies. Bayer Schering Pharma will provide two targets, and Dyax will identify related antibodies.

    Dyax will receive milestone payments and royalties. The deal also provides Bayer Schering Pharma with sublicenses to relevant third-party antibody phage display patents that may be used with Dyax' technology.

    These research activities may be expanded to allow Dyax to work on additional targets and/or allow Bayer Schering Pharma to exercise an option for an antibody library license.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »